686 results on '"Go, Ronald"'
Search Results
2. Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy
3. Isolated Nervous System Histiocytic Neoplasms: Clinical Manifestations, Treatment, and Outcomes (P4-5.018)
4. Blood Neurofilament Light Chain Measurements in Adults with CNS Histiocytic Neoplasms (P4-5.012)
5. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures
6. A machine-learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura
7. Comprehensive morphologic characterization of bone marrow biopsy findings in a large cohort of patients with VEXAS syndrome: A single-institution longitudinal study of 111 bone marrow samples from 52 patients
8. Pilot Prospective Study of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Vexas Syndrome
9. A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry
10. Erythrocytosis in Patients on Testosterone Therapy
11. BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis
12. Absolute neutrophil count (ANC) cutoff in cancer clinical trials: Implications for minority accrual in the United States (US).
13. Utilization of the medical oncology pager and call center: Characterizing forgotten pillars of telemedicine in the digital era.
14. Long-term outcomes among adults with Langerhans cell histiocytosis
15. Malignant Histiocytosis Comprises a Phenotypic Spectrum That Parallels the Lineage Differentiation of Monocytes, Macrophages, Dendritic Cells, and Langerhans Cells
16. P-448 Impact of molecular cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas
17. Reply
18. Genome‐wide association study identifies the first germline genetic variant associated with Erdheim Chester disease
19. P1105: NEUROLOGIC INVOLVEMENT IN ADULTS WITH ROSAI-DORFMAN DISEASE: CLINICAL PRESENTATION AND OUTCOMES
20. P1049: CHARACTERISTICS AND OUTCOMES OF CARDIOVASCULAR INVOLVEMENT IN ERDHEIM-CHESTER DISEASE
21. P903: CLINICAL UTILITY OF MONOCLONAL GAMMOPATHY SCREENING IN THE EVALUATION OF PERIPHERAL NEUROPATHY
22. PB2208: CLUSTER ANALYSIS UNVEILS THE CLINICAL SPECTRUM OF ERDHEIM-CHESTER DISEASE
23. Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis
24. Impact of Cytogenetic Abnormalities on the Risk of Disease Progression in Solitary Bone Plasmacytomas
25. Recurrent Tumefactive Central Nervous System Lesions Due to BRIP1-Related Fanconi Anemia
26. Pulmonary manifestations in VEXAS syndrome
27. Targeted testing of bone marrow specimens with cytoplasmic vacuolization to identify previously undiagnosed cases of VEXAS syndrome
28. Relationship of paroxysmal nocturnal hemoglobinuria (PNH) granulocyte clone size to disease burden and risk of major vascular events in untreated patients: results from the International PNH Registry
29. Spectrum of clonal hematopoiesis in VEXAS syndrome
30. Supplementary Table S1 from ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602)
31. Supplementary Table S1 from ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602)
32. Cutaneous involvement in VEXAS syndrome: clinical and histopathologic findings
33. Spectrum of second primary malignancies and cause-specific mortality in pediatric and adult langerhans cell histiocytosis
34. Analysis of Female Participant Representation in Registered Oncology Clinical Trials in the United States from 2008 to 2020
35. Terminal Complement Inhibition in the Management of Transplant-Associated Thrombotic Microangiopathy: Single-Center Experience
36. ANCA ‐associated vasculitis and VEXAS syndrome: a comment on the article by Muratore et al.
37. Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation
38. Ophthalmologic Involvement in Adults with Histiocytic Disorders
39. Not So Benign Cold Agglutinin Disease: New Direction for an Old Disease
40. The impact of Post-Transplant doxycycline in AL amyloidosis – updated results after Long-Term follow up
41. Daratumumab, Carfilzomib, Pomalidomide and Elotuzumab for the Treatment of POEMS Syndrome- The Mayo Clinic Experience
42. Sirolimus as frontline therapy for PTEN-mutated histiocytic sarcoma
43. Time to first treatment is an independent prognostic factor for Multiple Myeloma (MM)
44. Practical Anemia Bundle for Sustained Blood Recovery (PABST-BR) in critical illness: a protocol for a randomised controlled trial
45. Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients
46. Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy
47. Sarcopenia identified by computed tomography imaging using a deep learning–based segmentation approach impacts survival in patients with newly diagnosed multiple myeloma
48. Bortezomib and/or Daratumumab for Treatment of Refractory Autoimmune Hemolytic Anemia
49. Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma - MRD Negativity and Survival Outcomes
50. Immunoglobulin Heavy Chain Amyloidosis: Patient Characteristics and Outcomes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.